Etiologic heterogeneity of the psychoses: Is there a dopamine psychosis?

Neuropsychopharmacology

Volumn 16, Issue 3, 1997, Pages 191-201

  Garver, David L ^a,b   Steinberg, Joel L ^a,b   McDermott, Barbara E ^c   Yao, Jeffrey K ^d   Ramberg, Jane E ^b   Lewis, Steve ^e   Kingsbury, Steven J ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c TULANE UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

dopamine; heterogeneity; homovanillic acid; neuroleptic; psychosis; schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; HOMOVANILLIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

EID: 0031104975     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(96)00186-8     Document Type: Article

References (61)

1. American Psychiatric Association, Committee of Nomenclature and Statistics (1980): Diagnostic and Statistical Manual of Mental Disorders, ed 3, Washington, DC, APA
2. Amin F, Davidson M, Davis KL (1992): Homovanillic acid measurement in clinical research: A review of methodology. Schizophr Bull 18:123-148
3. Anden NE, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U (1970): Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 11:303-314
4. Anderson WH, Kuehnle JC, Catanzano DM (1976): Rapid treatment of acute psychosis. Am J Psychiatry 133:1076-1078
5. Angrist B, Gershon S (1977): Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects. Adv Biochem Psychopharmacol 16:677-680
6. Baker NJ, Stanton M, Adler LE, Gerhardt GA, Drebing C, Waldo M, Nagamoto H, Freedman R (1990): Sensory gating deficits in psychiatric inpatients: Relation to catecholamine metabolites in different diagnostic groups. Biol Psychiatry 27:519-528
7. Baldessarini RJ (1985): Antipsychotic agents. In Baldessarini RJ (ed), Chemotherapy in Psychiatry: Principles and Practice, ed 2, Cambridge, Harvard University Press, pp 14-92
8. Bianchetti G, Morselli PL (1978): Rapid and sensitive method for determination of haloperidol in human samples using nitrogen-phosphorus selective detection. J Chromatography 153:203-209
9. Bleuler E (1911): Dementia praecox, or the group of schizophrenias (trans. J Zinkin, 1950), New York, International Universities Press
10. Bowers MJ (1991): Characteristics of psychotic inpatients with high or low HVA levels at admission. Am J Psychiatry 148:240-243
11. Bowers MB Jr, Swigar ME (1987): Acute psychosis and plasma catecholamine metabolites. Arch Gen Psychiatry 44:190
12. Bowers MB, Swigar ME, Jatlow PI (1983): Sex differences in plasma homovanillic acid in acute psychosis. N Engl J Med 308:845-846
13. Bowers MB Jr, Swigar ME, Jatlow PI, Goicoechea N (1984): Plasma catecholamine metabolites and early response to haloperidol. J Clin Psychiatry 45:248-251
14. Bowers MB Jr, Swigar ME, Jatlow PI, Hoffman F, Goicoechea N (1986): Early neuroleptic response in psychotic men and women: Correlation with plasma HVA and MHPG. Comp Psychiatry 27:181-185
15. Chang WH, Scheinin M, Burns RS, Linnoila M (1983): Rapid and simple determination of homovanillic acid in plasma using high performance liquid chromatography with electrochemical detection. Acta Pharmacol Toxicol 53:275-279
16. Chang WH, Chen TY, Lin SK, Lung FW, Lin WL, Hu WH, Yeh EK (1990): Plasma catecholamine metabolites in Schizophrenics: Evidence for the two-subtype concept. Biol Psychiatry 27:510-518
17. Chang WH, Hwu HG, Chen TY, Lin SK, Lung FW, Chen H, Lin WL, Hu WH, Lin HN, Chien CP (1993): Plasma homovanillic acid and treatment response in a large group of schizophrenic patients. Schizophr Res 10:259-265
18. Creese I, Burt DR, Snyder SH (1976): Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483
19. Davidson M, Davis KL (1988): A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch Gen Psychiatry 45:561-563
20. Donlon PT, Tupin J (1974): Rapid "digitalization" of decompensated schizophrenic patients with antipsychotic agents. Am J Psychiatry 131:310-312
21. Doran A, Pickar D, Labarca R, Douillet R, Wolkowitz O, Thomas J, Roy A, Dane S (1985): Evidence for a daily rhythm of plasma HVA in normal controls but not in schizophrenic patients. Psychopharmacol Bull 21:694-697
22. Endicott J (1978): SADS Summary Scale Scores, ed 3, New York, New York State Psychiatric Institute
23. Endicott J, Spitzer RL (1978): A diagnostic interview: The Schedule for Affective Disorders and Schizophrenia (SADS). Arch Gen Psychiatry 35:837-884
24. Garver DL, Kelly K, Fried KA, Magnusson M, Hirschowitz J (1988): Drug response patterns as a basis of nosology for the mood-congruent psychoses (the schizophrenias). Psychological Med 18:873-885
25. Garver DL, Reich T, Isenberg KE, Cloninger CR (1989): Schizophrenia and the question of genetic heterogeneity. Schizophr Bull 15:421-429
26. Glovinsky D, Kirch DG, Wyatt RJ (1992): Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. Biol Psychiatry 31:968-970
27. Hollister LE, Overall JE, Bennett JL, Kimbell I Jr, Shelton J (1967): Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients. Clin Pharmacol Therapeutics 8:249-255
28. Janowsky DS, Davis JM (1976): Methylphenidate, dextroamphetamine, and levamfetamine: Effects on schizophrenic symptoms. Arch Gen Psychiatry 33:304-308
29. Karoum F, Karson CN, Bigelow LB, Lawson WB, Wyatt RJ (1987): Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. Arch Gen Psychiatry 44:604-607
30. Keck PE, Cohen BM, Baldessarini RJ, McElroy SL (1989): Time course of antipsychotic effects of neuroleptic drugs. Am J Psychiatry 146:1289-1292
31. Kopin IF, Bankiewicz KS, Harvey-White J (1988): Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment: Validation in monkeys treated with MPTP. Neuropsychopharmacology 1:119-125
32. Koreen AR, Lieberman J, Alvir J, Mayerhoff D, Loebel A, Chakos M, Amin F, Cooper T (1994): Plasma homovanillic acid levels in first-episode schizophrenia: Psychopathology and treatment response. Arch Gen Psychiatry 51: 132-138
33. Lerner Y, Lwow E, Levitin A, Belmaker RH (1979): Acute high-dose parenteral haloperidol treatment of psychosis. Am J Psychiatry 136:1061-1064
34. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M (1993): Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 50:369-376
35. Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR (1992): Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 149:1183-1188
36. Markianos M, Botsis A, Arvanitis Y (1992): Biogenic amine metabolites in plasma of drug-naive schizophrenic patients: Associations with symptomatology. Biol Psychiatry 32:288-292
37. Mason AS, Granacher RP (1976): Basic principles of rapid neuroleptization. Dis Nerv Sys 37:547-551
38. Mazure CM, Nelson JC, Jatlow PI, Bowers MB Jr (1992): Drug-responsive symptoms during early neuroleptic treatment. Psychiatry Res 41:147-154
39. Neborsky R, Janowsky D, Munson E, Depry D, Schooler NR, Goldberg SC (1981): Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Arch Gen Psychiatry 38:195-199
40. Overall JE, Gorham DR (1962): The brief psychiatric rating scale. Psychological Reports 10:799-812
41. Peralta V, deLeon J, Cuesta MJ (1992): Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy. Brit J Psychiatry 161:335-343
42. Pickar D, Labarca R, Linnoila M, Roy A, Hommer D, Everett D, Paul SM (1984): Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 225:954-957
43. Reschke RW (1973): Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Dis Nerv Sys 35:112-115
44. Reynolds GP (1983): Increased concentrations and lateral asymmetry of amydgala dopamine in schizophrenia. Nature 305:527-529
45. Sautter F, Hitzemann R, Griffin J, Garver DL (1986): Lithium ratio in vitro: Familial patterns of illness. Psychiatry Res 18:257-266
46. Scheinin M, Chang WH, Kirk KL, Linnoila M (1983): Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acids in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection. Analyt Biochem 131:246-253
47. Seeman P, Chau-Wong M, Tedesco J, Wong K (1975): Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc Nat Acad Sci U S A 72:4376-4380
48. Seeman P, Ulpian C, Bergeron C, Riederer P, Jellinger K, Gabriel E, Reynolds GP, Tourtellotte WW (1984): Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 225(4663):728-731
49. 4 receptors elevated in schizophrenia. Nature 365:441-445
50. SigmaStat for Windows (1992-1994): User's Manual, San Rafael, Ca, Jandel Scientific
51. 2 dopamine receptors in drug naive schizophrenics. Science 234:1558-1563
52. Steinberg JL, Garver DL, Moeller FG, Raese JD, Orsulak PJ (1993): Serum homovanillic acid levels in schizophrenic patients and normal control subjects. Psychiatry Res 48:93-106
53. Stone CK, Garver DL, Griffith J, Hirschowitz J, Bennett J (1995): Further evidence of a dose-response threshold for haloperidol in psychosis. Am J Psychiatry 152:1210-1212
54. SYSTAT for Windows (1992): Getting Started, Version 5 Edition, Evanston, IL, SYSTAT, Inc.
55. Van Kammen DP, Bunney WE Jr, Docherty JP, Marder SR, Ebert MH, Rosenblatt JE, Rayner JN (1982): d-amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. Am J Psychiatry 139:991-997
56. Van Putten T, Marder SR, Aravagiri M, Chabert N, Mintz J (1989): Plasma homovanillic acid as a predictor of response to fluphenazine treatment. Psychological Bull 1:89-91
57. Van Rossum JM (1967): The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In Brill H, Cole J, Deniker P, Hippius H, Bradley PB (eds), Proceedings of the Fifth Collegium Internationale Neuropsychopharmacologicum, Amsterdam, Excerpta Medica Foundation, pp 321-329
58. Wei J, Ramchand CN, Hemmings GP (1992): Studies on concentrations of NA and HVA and activity of DBH in the serum from schizophrenic patients, first-degree relatives and normal subjects. Schizophr Res 8:103-110
59. Whelton CL, Gupta RN, Cleghorn JM, Ballagh SR (1993): Influence of renal clearance on peripheral homovanillic acid measurements in healthy subjects and schizophrenic patients. Schizophr Res 11:33-40
60. Winer BJ, Brown DR, Michels KM (1991): Statistical Principles in Experimental Design, New York, McGraw-Hill, Inc.
61. 2 dopamine receptors in drug-naive schizophrenics. Science 234:1558-1563